Power3 Medical Products, Inc. (OTC:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that Power3 Medical Products has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 Medical Products plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3 Medical Products, with Power3 Medical Products remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).
Advantest Corporation (NYSE:ATE), the world’s leading supplier of semiconductor test equipment, and OptimalTest, the leader in Advanced Adaptive Test® and enterprise-wide test management and optimization software for the semiconductor industry, disclose the availability of OptimalTest’s solutions for totally automated, integrated advanced adaptive test on Advantest’s T2000 High Performance Open Architecture test platform. By enabling T2000 testers and test cells with OptimalTest’s solutions, Advantest will augment the T2000’s industry-recognized high performance and cost benefits for SoC production test with the ability to achieve further significant improvements in yield; early detection of product, process and operational issues; reliability; reduced test time; production quality and Overall Equipment Efficiency (OEE) while keeping test costs low.
Advantest Corporation is the world’s leading automatic test equipment supplier to the semiconductor industry, and also produces electronic instruments and systems.
Micromet, Inc. (NASDAQ:MITI) reported that its licensee for MT111, MedImmune, plans to initiate a Phase 1 trial in patients with advanced gastrointestinal cancers based on an investigational new drug (NYSE:IND) application recently accepted by the U.S. Food and Drug Administration (FDA). MT111, also known as MEDI-565, is a BiTE® antibody designed to direct a patient's T cells, the body’s most potent killer cells, against cancer cells that express carcinoembryonic antigen (NYSE:CEA). CEA is a protein found on the surface of a number of gastrointestinal cancers, including colorectal, esophageal and gastric.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer.
Micron Technology, Inc., (Nasdaq:MU) reported results of operations for its fourth quarter and 2010 fiscal year, which ended September 2, 2010. For the fourth quarter, Micron Technology had net income attributable to Micron Technology shareholders of $342 million, or $0.32 per diluted share, on net sales of $2.5 billion, and generated a quarterly record $1.1 billion in cash flows from operations. The results for the fourth quarter of fiscal 2010 compare to net income of $939 million (including $488 million in gains from the Numonyx acquisition), or $0.92 per diluted share, on net sales of $2.3 billion for the third quarter of fiscal 2010, and a net loss of ($100) million, or ($0.12) per diluted share, on net sales of $1.3 billion for the fourth quarter of fiscal 2009.
Micron Technology, Inc., is one of the world's leading providers of advanced semiconductor solutions.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (OTC:PWRM). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (OTC:PWRM). Each advertising commitment has now expired.